Sinergium provides gateway to Latin American vaccine and biologics markets

May 9, 2017 Christoph Graener

With the Latin American vaccines market forecast to more than quadruple in size from just over USD 150 million to 2015 to just under USD 700 million in 2020, opportunities abound for both homegrown businesses and multinationals looking to tap into local markets. Fernando Lobos, business development director of Sinergium Biotech, an Argentine biopharmaceutical company specializing in the research, development, production and marketing of vaccines and highly complex biopharmaceuticals, revealed to Scrip’s Mike Ward, how the company can be a gateway to the Latin American market for both multinationals and smaller biotechs. Sinerguim has one manufacturing plant in operation and another one under construction. It has already signed deals with Novartis, to supply vaccines that can combat various influenza strains; Merck Sharp & Dohme for the production of its tetravalent vaccine against HPV; and Pfizer for the production of its pneumococcal conjugate vaccine. Last year, the company entered into an agreement with Protein Sciences Corporation and Mundo Sano for the joint development of a vaccine against the Zika virus.

Previous Article
Shanghai Henilus Biotech has blockbuster biologics in biosimilar crosshairs

Dr. Cheni Kwok, a business development and strategy consultant, caught up with Scrip’s Mike Ward to outline...

Next Article
Korean pharma spawns US cancer biotech startup

Dr. Benjamin R Cowen, COO of ImmunoMet Therapeutics, reveals how the Houston-based startup is developing OX...